GSA Capital Partners LLP Decreases Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

GSA Capital Partners LLP decreased its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 79.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,934 shares of the company's stock after selling 87,851 shares during the quarter. GSA Capital Partners LLP's holdings in Health Catalyst were worth $187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of HCAT. Nisa Investment Advisors LLC increased its holdings in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP increased its holdings in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC bought a new position in Health Catalyst in the third quarter valued at $59,000. Perfromance Wealth Partners LLC bought a new position in Health Catalyst in the second quarter valued at $64,000. Finally, Mackenzie Financial Corp bought a new position in Health Catalyst in the second quarter valued at $70,000. Institutional investors own 85.00% of the company's stock.

Health Catalyst Stock Performance

Shares of HCAT stock traded up $0.33 during trading hours on Monday, hitting $8.46. 256,666 shares of the company's stock traded hands, compared to its average volume of 560,038. The stock's fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $7.27. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analysts' expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst's revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. As a group, sell-side analysts predict that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Insider Activity

In other news, insider Kevin Lee Freeman sold 7,500 shares of the company's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock valued at $257,555 in the last 90 days. Company insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HCAT. Piper Sandler reduced their target price on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday, August 26th. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Cantor Fitzgerald restated an "overweight" rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada upped their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Finally, Stephens upped their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst has an average rating of "Moderate Buy" and an average price target of $11.71.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.